Business
Hikma launches Icosapent Ethyl Capsules
Hikma launches Icosapent Ethyl Capsules.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3599E\n Hikma Pharmaceuticals Plc\n 05 November 2020\n \n \n \n \n \n London, 5 November\n \n \n , 2020\n \n \n - \n Hikma Pharmaceuticals PLC\n (Hikma), the multinational pharmaceu\n tical company, has launched\n Icosapent Ethyl Capsules\n , 1gm, in the US through its \n US affiliate, Hikma Pharmaceuticals USA Inc.\n \n \n \n Following an earlier than expected favorable court ruling, Hikma has accelerated the launch of its Icosapent Ethyl Capsules in order to quickly provide patients with access to this important medicine. Initially, Hikma will be releasing limited quantities to ensure a consistent supply for customers. The Company is working to scale up manufacturing and increase availability as soon as possible.\n \n \n \n \n \n \"Hikma's launch of this important medicine for US patients and healthcare providers once again underscores our ability to put better health, within reach, every day for millions of people who rely on our medicines,\" said Brian Hoffmann, President of Hikma Generics. \"Today's launch demonstrates Hikma's ability to successfully challenge patents and launch complex products, bringing greater value to our customers and patients.\"\n \n \n \n \n \n Hikma's FDA-approved I\n cosapent Ethyl C\n apsule product is indicated for the following indication: as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Hikma's product is not approved for any other indication for the reference listed drug VASCEPA®. \n \n \n \n \n \n - ENDS -\n \n \n \n \n \n Enquiries \n \n \n Hikma Pharmaceuticals PLC \n \n \n \n \n \n Susan Ringdal\n \n \n EVP, Strategic Planning and Global Affairs\n \n \n \n \n +44 (0)20 7399 2760/ +44 7776 477050\n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n Steve Weiss\n \n \n David Belian\n \n \n US Communications and Public Affairs \n \n \n \n \n +1 732 720 2830/ +1 732 788 8279\n \n \n +1 732 720 2814/+1 848 254 4875\n \n \n \n u\n \n \n scommunications\n \n \n @hikma.com\n \n \n \n \n \n \n \n \n \n \n \n \n \n About Hikma\n \n (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)\n \n \n \n \n \n Hikma helps put better heal...